Oppenheimer raised the firm’s price target on Praxis Precision (PRAX) to $750 from $250 and keeps an Outperform rating on the shares. The firm sees substantial momentum building for Praxis as recent clinical and regulatory updates derisk large commercial opportunities that it believes remain undervalued. Praxis now plans an NDA filing in early 2026 for relutrigine in SCN2A/8A patients following FDA discussions, enabling approval and launch in 2027. Oppenheimer believes the positive Phase 2/3 EMBOLD study and critical need for treatment support accelerated uptake and a high value proposition to payors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Praxis Precision price target raised to $313 from $303 at Deutsche Bank
- Praxis Precision Medicines Plans New Drug Application
- Praxis Precision achieves alignment on elsunersen pathway following FDA meeting
- Praxis Precision price target raised to $450 from $300 at Jefferies
- Praxis Precision Medicines: Promising Epilepsy Portfolio Advances Justify Buy Rating